

4. (Amended)

a1 A method of treating a patient suffering from diabetic cardiomyopathy, comprising administering a therapeutically effect amount of a GLP-1 molecule to a patient suffering from diabetic cardiomyopathy.

Please add new claims 10-16:

10. (New)

The method of claim 6 whereby the GLP-1 molecule is administered in a dose of from about 0.1-10 pmol/kg/min.

11. (New)

The method of claim 4 whereby the GLP-1 molecule is administered subcutaneously in a dose of from about 0.5-50 pmol/kg/min.

a2 12. (New)

The method of claim 4 whereby the GLP-1 molecule is administered in a dose of up to 10.0 nmol/kg.

13. (New)

A method of treating a patient suffering from diabetic cardiomyopathy, comprising administering up to 10.0 nmol/kg of a GLP-1 molecule to a patient suffering from diabetic cardiomyopathy.

14. (New)

The method of claim 13 whereby the GLP-1 molecule is administered intravenously in a dose of from about 0.1-10 pmol/kg/min.

15. (New)

The method of claim 13 whereby the GLP-1 molecule is administered subcutaneously in a dose of from about 0.5-50 pmol/kg/min.

a2

16. (New)

The method of claim 13 whereby the GLP-1 molecule is GLP-1 (7-36) amide.

